About Black Diamond Therapeutics. The 52-week high for the BDTX s According to TipRanks.com, Lee is a 4-star analyst with an average return of 9.6% and a 47.5% success rate. How has Black Diamond Therapeutics's share price performed over time and what events caused price changes? Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium Globe Newswire 10/26 07:45 ET Black Diamond Therapeutics's lead asset data to be presented in an upcoming symposium Black Diamond Therapeutics Inc., which has a market valuation of $474.39 million. Get Black Diamond Therapeutics Inc (BDTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. CAMBRIDGE, Mass. To access the presentation, please … The Chairman Robert Ingram made the biggest insider purchase in the last 12 months. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. News Release Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update. Black Diamond Therapeutics Inc., a precision oncology medicine company, has inked a lease for more than 18,000 square feet in Kips Bay. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Dr. Kapil Dhingra to its Board of Directors.Dr. Black Diamond Therapeutics, Inc. is an equal opportunity employer. Black Diamond … Other News. Black Diamond Equipment. Black Diamond Therapeutics Inc. [NASDAQ: BDTX] stock went on a downward path that fall over -14.79% on Tuesday, amounting to a one-week price decrease of less than -6.86%. Looking at the last year, the company burnt through US$29m. CAMBRIDGE, Mass. Black Diamond Therapeutics Inc. (NASDAQ: BDTX) stock closed at 12.83 per share at the end of the most recent trading day (a 1.34 % change compared to the prior day closing price) with a volume of 862.55K shares and market capitalization of 463.96M.Is a component of indices and it is traded on NASDAQ exchange. This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash. Black Diamond Therapeutics, Inc. (BDTX) Shares March Higher, Can It Continue? The company report on January 5, 2021 that Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Confe Black Diamond Therapeutics Inc. (BDTX) shares plunged 18.58% to trade at $18.1 in the after-market on Wednesday, May 19, 2021. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond Therapeutics Inc. [NASDAQ: BDTX] stock went on a downward path that fall over -3.89% on Tuesday, amounting to a one-week price decrease of less than -7.42%. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. PDF Version. In its first day of trading, the cancer drug developer watched its shares soar more than 108 percent. CAMBRIDGE, Mass. If you are a California consumer, you have the right, at any time, to direct a business that sells your personal information to third parties to not sell your personal information. and NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth … Black Diamond Therapeutics to offer 8.9 million shares in planned IPO, priced at $16 to $18 each. Black Diamond Therapeutics Inc. $12.83 +1.34%. Black Diamond discovers and develops next-wave precision cancer medicines to treat patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Black Diamond Therapeutics (BDTX – Research Report) yesterday and set a price target of $50.00.The company’s shares closed last Thursday at $13.93, close to its 52-week low of $13.27. Latest Share Price and Events. Black Diamond Therapeutics, Inc. stock news. Black Diamond Therapeutics Inc (BDTX) stock is trading at $23.67 as of 2:13 PM on Tuesday, May 18, a loss of -$1.39, or -5.57% from the previous closing price of $25.06. At the end of the latest market close, Black Diamond Therapeutics Inc. (BDTX) was valued at $13.65. Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial. A little more than a year ago, Black Diamond Therapeutics unveiled technology that analyzes genetic data to discover new cancer drugs. Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology. Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update. That single transaction was for US$152k worth of shares at a price of US$30.46 each. and NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that it will host a webcast … CAMBRIDGE, Mass. Black Diamond Therapeutics Inc is a precision oncology medicine company. Versant Ventures today announced that Black Diamond Therapeutics completed an IPO on NASDAQ, raising $201 million through the sale of 10.6 million sha Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) has completed its initial public offering (IPO) on NASDAQ, raising US $201 million through the issuance of 10.6 million shares at US $19 per share. 11/10/2020 7:49:00 AM Black Diamond Therapeutics Q3 Loss/Shr $0.50 Vs Loss $4.50 Last Year 9/8/2020 4:12:07 PM Black Diamond Therapeutics Appoints Rachel Humphrey As … Get the hottest stocks to … Zacks News for BDTX No Record found. The Chairman Robert Ingram made the biggest insider purchase in the last 12 months. Net cash used in operations was $24.5 million for the first quarter … N/A. Get the hottest stocks to … Black Diamond Therapeutics raises $85M in Series B funding The raise comes a month after the Cambridge, Massachusetts-based firm's launch with … Apr 8, 2021. Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) shares, dropped in value on Thursday, May 20, with the stock price down by -37.34% to the previous day’s close as weak demand from buyers trailed the stock to $13.93. Black Diamond targets undrugged mutations in patients with genetically defined cancers. The company report on January 5, 2021 that Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Confe Black Diamond Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.50, which is a 106.2% upside from current levels. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy … Black Diamond Therapeutics Inc., a Stony Brook University incubator company that has attracted more than $100 million in venture capital to develop targeted cancer drugs, is … Claim your 1-week free trial to StreetInsider Premium here . Wall Street brokerages predict that Black Diamond Therapeutics (NASDAQ:REYN) will announce $798.38 million in sales for the current quarter, Zacks reports. Today the … The stock has traded between $23.66 and $26.43 so far today. Black Diamond Therapeutics Inc BDTX Vitals. Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting. Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting finance.yahoo.com - March 10 at 7:38 PM Black Diamond Therapeutics, Inc. Black Diamond Therapeutics (BDTX) has an average rating of buy and price targets ranging from $24 to … That means that an insider was happy to buy shares at above the current price of US$24.16. BDTX : 12.78 (+0.47%) Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium GlobeNewswire - Mon Oct 26, 2020. Company Summary. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Dr. Kapil Dhingra to its Board of Directors. By Benzinga - Mar 10, 2021. Start your job search here. Black Diamond Therapeutics Inc is a precision oncology medicine company. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Dr. Kapil Dhingra to its Board of Directors. Black Diamond ended the first quarter of 2021 with $290.1 million in cash, cash equivalents, and investments compared to $357.2 million as of March 31, 2020. The company’s stock price has collected -20.18% of loss in the last five trading sessions. CAMBRIDGE, Mass. Black Diamond Therapeutics Inc is a precision oncology medicine company. Black Diamond Therapeutics Inc. (BDTX) Insider Activity. A high-level overview of Black Diamond Therapeutics, Inc. (BDTX) stock. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Description: Black Diamond Therapeutics Inc is a precision oncology medicine company. Special Events. Company to host conference call on Wednesday, May 19, 2021 at 6:00 PM ET. Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Jan. 21, 2020 at 8:33 a.m. ET by Ciara Linnane. CAMBRIDGE, Mass. CAMBRIDGE, Mass. The company, currently valued at $484.58 Million, closed the last trade at $13.4 per share which meant it lost -$0.53 on the day or … Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has a beta value of 0 and has seen 4,051,846 shares traded in the last trading session. Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. May 7, 2021. by Zacks Equity Research Published on May 05,2020 As of … Black Diamond Therapeutics said in its filings that it plans to use the IPO proceeds to develop its BDTX-189 cancer medicine, with a combined phase 1/2 clinical trial starting in … SEC Filings provided by EDGAR Online, Inc. Prev Page Next Page. It engages in discovery and … The company belongs in the Biotechnology industry, Healthcare sector and … Industry: Biotechnology. Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) shares, dropped in value on Thursday, May 20, with the stock price down by -37.34% to the previous day’s close as weak demand from buyers trailed the stock to $13.93. Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. The Last 12 Months Of Insider Transactions At Black Diamond Therapeutics. A live webcast presentation will be available on the News & Events section of the Black Diamond website at www.blackdiamondtherapeutics.com. The stock current value is … Earlier, BDTX’s stock lost 4.63% to close Wednesday’s normal session at $22.23 per share. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the presentation of preclinical data on BDTX-189 and BDTX-1535 at the American Association for Cancer Research … Get Black Diamond Therapeutics Inc (BDTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Black Diamond Therapeutics plans to list on the Nasdaq, the exchange of choice for most biotechs. Data delayed 15 minutes ... U.S. News has analyzed over 4,500 stocks to help investors reach their financial goals. Company profile page for Black Diamond Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information About Black DiamondBlack Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that it will host a webcast presentation on Wednesday, May 19, 2021 at 6:00 PM ET to discuss pharmacokinetic, safety, and preliminary efficacy data from the Phase 1 H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Black Diamond Therapeutics (BDTX – Research Report) today and set a price target of $53.00.The company’s shares closed last Wednesday at $22.23, close to its 52-week low of $21.04. The Cambridge, Massachusetts -based company said it had a loss of 84 cents per share. Black Diamond Therapeutics (NASDAQ: BDTX) shares have tumbled nearly 30% in premarket trading after the company posted early-stage results of … SEC Filings for Black Diamond Therapeutics Inc. That single transaction was for US$152k worth of shares at a price of US$30.46 each. SC 13G. Mar 25, 2021. At the last check today, the stock’s price was $14.41, reflecting an intraday loss of -35.18% or -$7.82. Stock analysis for Black Diamond Therapeutics Inc (BDTX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Its drugs under pipeline are BDTX-189 and BDTX-1535. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. BDTX's rank also includes a short-term technical score of 10. 2 … 02/03/2020. Following the sale, the insider now owns 12,478 shares in the company, valued at $311,950. Get the hottest stocks to trade every day … May 7, 2021 . (AP) _ Black Diamond Therapeutics, Inc. (BDTX) on Friday reported a loss of $30.3 million in its first quarter. The company has one pipeline technology platform namely, Mutation-Allostery-Pharmacology which is … Market news. Company Name Black Diamond Therapeutics (BDTX) Black Diamond Therapeutics Inc. (BDTX) Analyst Forecasts. In March 2020, Black Diamond Therapeutics had US$357m in cash, and was debt-free. Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, MasterKey therapies. Get instant alerts when news breaks on your stocks. BDTX's rank also includes a long-term technical score of 0. The results fell short of Wall Street expectations. We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely. Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. In a report issued on January 18, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target. Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update. About Black Diamond Therapeutics. BDTX shares have fallen 39.44% over the last 12 … Over the past year the S&P 500 is up 17.45% while BDTX is down -33.61%. In total Black Diamond Therapeutics has raised $408.2M. Financial Highlights. The stock current value is … During the recent session, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)’s traded shares were 5,574,392, with the beta value of the company hitting 0. Black Diamond Therapeutics was the first company to emerge from Ridgeline, Versant Ventures’ Discovery Engine based in the Basel Technology Park. Nasdaq. Black Diamond Therapeutics Inc stock is down -39.93% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives BDTX stock a score of 33 out of a possible 100.. That rank is primarily influenced by a long-term technical score of 3. CAMBRIDGE, Mass. In total Black Diamond Therapeutics has raised $408.2M. Arlinda Lee, analyst at Canaccord Genuity, reiterated coverage on Black Diamond Therapeutics (NASDAQ:BDTX) in the Healthcare sector with a Buy rating. Dhingra has more than 30 years’ experience in oncology … Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) insider Brent Hatzis-Schoch sold 4,078 shares of the company’s stock in a transaction dated Monday, April 12th. Wedbush removed Black Diamond Therapeutics (NASDAQ: BDTX ) from its Best Ideas List Since Black Diamond Therapeutics was founded in 2016, it has participated in 6 rounds of funding. Company to host conference call on Wednesday, May 19, 2021 at 6:00 PM ET CAMBRIDGE, Mass.
Types Of Roof Valley Flashing, Agoraphobia Pronunciation, University Of Kentucky Average Act, Trinity House Lighthouse, Paramount Pictures Studio, Structural Plains Examples,
Leave a Reply